Mammogram Facilities, Tumor Biology Linked to the Racial Disparity in Breast Cancer
the Cancer Therapy Advisor take:
Screening facility resources and aggressiveness of tumors were identified as being two major factors that explain racial/ethnic disparity among patients recently screened for symptomatic breast cancer, according to an article published online in the journal Cancer Epidemiology, Biomarkers & Prevention.
Participants in this study included patients recently diagnosed with breast cancer and analyzed regarding the probability of symptomatic awareness despite a recent screening mammogram (SADRS). Patients who did not report a recent prior screening were not included in the study analyses.
Results showed SADRS was more common among nH b P=0.0004). Furthermore, an association was identified between SADRS and estrogen and progesterone receptor (ER/PR) negative status and higher grade disease.
SADRS was less likely to be reported at centers with dedicated radiologists and site that were labeled as breast imaging centers of excellence.
Two-thirds of the racial/ethnic disparity in SADRS was explained by tumor biology and facility factors (proportion mediated=70%, P=0.02).
Screening facility resources and aggressiveness of tumors identified as being two major factors that explain racial disparity in breast cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Breast Implant-Associated Anaplastic Large Cell Lymphoma — In the Clinic
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- 5α-Reductase Inhibitors Do Not Increase Risk of High-Grade Prostate Cancer
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC
- Model May Identify Patients With Gastric Cancer Likely To Benefit From Chemotherapy